These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Dynorphin-A-(1-13) antagonizes morphine analgesia in the brain and potentiates morphine analgesia in the spinal cord. Ren MF; Lu CH; Han JS Peptides; 1985; 6(6):1015-20. PubMed ID: 2871545 [TBL] [Abstract][Full Text] [Related]
23. Response of rat globus pallidus neurons to microintophoretically applied mu and kappa opioid receptor agonists. Huffman RD; Frey JM Eur J Pharmacol; 1989 Nov; 170(3):179-91. PubMed ID: 2575994 [TBL] [Abstract][Full Text] [Related]
24. Suppression of morphine withdrawal by electroacupuncture in rats: dynorphin and kappa-opioid receptor implicated. Wu LZ; Cui CL; Tian JB; Ji D; Han JS Brain Res; 1999 Dec; 851(1-2):290-6. PubMed ID: 10642860 [TBL] [Abstract][Full Text] [Related]
25. Physical dependence liability of dynorphin A analogs in rodents. Nakazawa T; Kaneko T; Yoshino H; Tachibana S; Goto M; Taki T; Yamatsu K Eur J Pharmacol; 1991 Aug; 201(2-3):185-9. PubMed ID: 1686757 [TBL] [Abstract][Full Text] [Related]
26. Opioid antagonists: indirect antagonism of morphine analgesia by spinal dynorphin A. Aksu F; Holmes BB; Fujimoto JM Pharmacol Biochem Behav; 1993 Jun; 45(2):409-18. PubMed ID: 8101007 [TBL] [Abstract][Full Text] [Related]
27. Dynorphin-(1-13) restores the potency of morphine on the tolerant guinea pig ileum. Rezvani A; Way EL Eur J Pharmacol; 1984 Jul; 102(3-4):475-9. PubMed ID: 6149134 [TBL] [Abstract][Full Text] [Related]
28. Modulation of acute morphine tolerance by corticotropin-releasing factor and dynorphin A in the mouse spinal cord. Song SH; Takemori AE Life Sci; 1992; 51(2):107-11. PubMed ID: 1352026 [TBL] [Abstract][Full Text] [Related]
29. Intrathecal dynorphin A1-13 and dynorphin A3-13 reduce rat spinal cord blood flow by non-opioid mechanisms. Long JB; Kinney RC; Malcolm DS; Graeber GM; Holaday JW Brain Res; 1987 Dec; 436(2):374-9. PubMed ID: 2893653 [TBL] [Abstract][Full Text] [Related]
30. Hypothermia elicited by some prodynorphin-derived peptides: opioid and non-opioid actions. Cavicchini E; Candeletti S; Spampinato S; Ferri S Neuropeptides; 1989 Jul; 14(1):45-50. PubMed ID: 2571107 [TBL] [Abstract][Full Text] [Related]
31. Brain reward deficits accompany naloxone-precipitated withdrawal from acute opioid dependence. Liu J; Schulteis G Pharmacol Biochem Behav; 2004 Sep; 79(1):101-8. PubMed ID: 15388289 [TBL] [Abstract][Full Text] [Related]
32. Specific N- or C-terminus modified dynorphin and beta-endorphin peptides can selectively block excitatory opioid receptor functions in sensory neurons and unmask potent inhibitory effects of opioid agonists. Shen KF; Crain SM Brain Res; 1995 Feb; 673(1):30-8. PubMed ID: 7757476 [TBL] [Abstract][Full Text] [Related]
33. Is withdrawal hyperalgesia in morphine-dependent mice a direct effect of a low concentration of the residual drug? Rubovitch V; Pick CG; Sarne Y Addict Biol; 2009 Sep; 14(4):438-46. PubMed ID: 19489750 [TBL] [Abstract][Full Text] [Related]
35. Comparison with naloxone of two dynorphin A analogues with K- and delta-opioid antagonist activity. Capasso A Med Chem; 2009 Jan; 5(1):1-6. PubMed ID: 19149644 [TBL] [Abstract][Full Text] [Related]